Literature DB >> 18778497

Significant alterations of serum cytokine levels in patients with Peyronie's disease.

Reinhold P Zimmermann1, Gerhard Feil, Conny Bock, Lorenz Hoeltl, Arnulf Stenzl.   

Abstract

OBJECTIVE: To determine the expression of the cytokines transforming growth factor-beta1 (TGF-beta1), interferon-gamma (IFN-gamma), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in serum from patients with Peyronie's disease (PD) compared to healthy controls.
MATERIALS AND METHODS: Ninety-one consecutive PD patients aged 20 - 74 years were included in this study. All patients were diagnosed with symptomatic PD for the first time and had a palpable penile plaque. The patients previously had the disease for 6 - 72 months. None of the patients had a severe infectious disease or known systemic illness. For cytokine analyses, peripheral venous blood samples were obtained before treatment. Fifty healthy male blood donors aged 22 - 64 years served as the control group. TGF-beta1, IFN-gamma, Il-6, and TNF-alpha were analyzed quantitatively with commercial immunoassays.
RESULTS: Mean cytokine levels in serum from patients were increased for TGF-beta1 and IFN-gamma compared to healthy controls. The difference for TGF-beta1 was considered statistically significant (p < 0.001). IL-6 was not detectable in PD patients (p < 0.01) and TNF-alpha was decreased (p < 0.0001).
CONCLUSION: The significantly elevated serum level of the profibrotic TGF-beta1 cytokine underscores the effect of cytokines in the pathophysiology of PD. The significantly decreased TNF-alpha serum level suggested no acute immunomodulatory process. Therefore, the relevance for therapeutic administration of TNF-alpha should be further investigated. Quantification of TGF-beta1 in serum of PD patients provides a possible diagnostic tool and target for therapy. The data on altered cytokine levels in PD patients also provide a new understanding for etiopathogenesis of PD, which warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18778497     DOI: 10.1590/s1677-55382008000400008

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  6 in total

1.  Is Peyronie's an IgG4-related disease?

Authors:  Mehmet Solakhan; Bünyamin Kısacık
Journal:  Eur J Rheumatol       Date:  2020-07-27

2.  The contribution of the immune system to genitourinary fibrosis.

Authors:  Karen M Doersch; Daniel Barnett; Abbie Chase; Daniel Johnston; J Scott Gabrielsen
Journal:  Exp Biol Med (Maywood)       Date:  2022-05-07

3.  Clinical and epidemiological characteristics of young patients with Peyronie's disease: a retrospective study.

Authors:  Gianni Paulis; Giorgio Cavallini; Davide Barletta; Paolo Turchi; Antonio Vitarelli; Andrea Fabiani
Journal:  Res Rep Urol       Date:  2015-07-09

4.  Bioinformatics-Based Identification of Potential Hypoxia-Related Genes Associated With Peyronie's Disease.

Authors:  Yuanshan Cui; Yajuan Wang; Changping Men; Jitao Wu; Lingling Liu
Journal:  Am J Mens Health       Date:  2022 Jul-Aug

5.  Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study.

Authors:  Gianni Paulis; Davide Barletta; Paolo Turchi; Antonio Vitarelli; Giuseppe Dachille; Andrea Fabiani; Romano Gennaro
Journal:  Res Rep Urol       Date:  2015-12-31

6.  Clinical use of hyaluronic acid in andrology: A review.

Authors:  Alessandro Zucchi; Fabrizio Ildefonso Scroppo; Paolo Capogrosso; Andrea Salonia; Jacopo Duante; Vittorio Bini; Giovanni Liguori; Riccardo Bartoletti
Journal:  Andrology       Date:  2021-08-02       Impact factor: 4.456

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.